Bernstein Raises PT on CVS Health (CVS) to $91, Reiterates 'Market Perform' Rating

CVS Health Corporation (NYSE:CVS) is one of the most undervalued blue chip stocks to buy now.

On January 6, 2026, Bernstein increased its price target on CVS Health Corporation (NYSE:CVS) from $87 to $91, while reiterating a ‘Market Perform’ rating. The investment firm expects a broader inflection in the government-managed care organization (MCO) sector beginning in 2026. The firm projects short-term earnings recovery, driven by Medicare Advantage (MA) and compelling valuations offered by Medicaid, despite an uneven recovery path. Amid this outlook, CVS appears well-positioned to be a key beneficiary of this shift, thanks to its diversified exposure across MA, Medicaid, and services.

Reinforcing that constructive stance, on January 7, 2026. Cantor Fitzgerald named CVS Health Corporation (NYSE:CVS) as one of its preferred MA exposure plays for this year. The firm’s optimism reflects a more favorable regulatory backdrop. Cantor Fitzgerald sees increased earnings visibility due to upcoming sector catalysts, including CMS enrollment data in mid-February and the preliminary MA rate notice in late January or early February 2026.

On the other hand, analysts from Wells Fargo recently projected declining post-pandemic tailwinds and subsidy risks. As a result, the firm downgraded CVS’s peers Humana and Universal Health Services. At the same time, the firm named CVS and UnitedHealth as two companies that are likely to benefit from the MA recovery.

CVS Health Corporation (NYSE:CVS), a diversified healthcare solutions provider, spans insurance benefits, pharmacy benefit management, retail pharmacy, clinics, and consumer wellness, integrating care delivery, services, and coverage at scale.

While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 7 Best Rising Tech Stocks to Buy Now and 12 Best Multibagger Stocks to Buy Heading into 2026.

Disclosure: None.